Dylan is an entrepreneur and the founder of Anivive Lifesciences, a biotech company that delivers innovative vaccines and treatments for unmet medical needs in pets. Utilizing cutting-edge technology such as AI, proprietary software, and veterinary medicine, Anivive has recently achieved a significant milestone in receiving FDA approval for the first Canine Oral Lymphoma Tablet. This approval is a testament to the company's dedication to pet health and its ability to deliver results. Anivive, in collaboration with the University of Arizona and the National Institutes of Health, is developing the 1stsystemic fungal vaccine for man or animal. This represents a groundbreaking advancement in medicine. The vaccine targets Valley Fever, a severe fungal infection impacting millions of dogs in the Southwestern United States, particularly in Arizona, where it is most prevalent. This endeavor will serve as a foundation for future vaccine development for human use. Before founding Anivive, Dylan co-founded The PetLawn, a consumer pet products business. His deep understanding of the pet industry and his unwavering commitment to animal health have positioned him to lead Anivive in delivering innovative solutions that improve the lives of pets and their owners. He currently serves on the board of directors of the Animal Health Institute (AHI), an organization dedicated to advancing the health and well-being of animals through research and education. With his passion for animal health and entrepreneurial spirit, Dylan is a leader in the pet industry, working tirelessly to improve the lives of pets and their owners.